The consumer genomics firm Helix will use an FDA-cleared device from OraSure's subsidiary DNA Genotek for collecting DNA samples from customers.
The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.
The company has decided to put its direct-to-consumer sequencing campaign on hold after receiving a letter from the FDA.
The new company believes it can be the dominant clearinghouse for genome analysis apps or other tools, with free and unlimited storage of users' genomic data.
As many as 10,000 Nevadans will get free genetic testing through a large population health study being conducted by non-profit care network Renown Health.
Early backers can get their genome or exome sequenced at discounted rates of $999 and $399, respectively, limited to the first 10 and 50 users in each case.
The company has developed a panel of 15 genes, identified from scientific literature, that specifically link to an athlete's potential to respond to power or endurance training.
Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.
Portable's mobile app allows patients to capture genotype, phenotype, and other data, and potentially profit from sharing it with interested third parties.
The price of WGS is at that "magic number" everyone has been waiting for, but is it enough to take genomics mainstream?
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.